Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma
18/9 17:01
(RTTNews) - Merck & Co., Inc. (MRK) said that the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with the company's anti-PD-1 therapy Keytruda, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS...